NCT05906758 Ultra-Low Contrast Angiography in AKI
| NCT ID | NCT05906758 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Tulane University |
| Condition | Acute Kidney Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2025-09-05 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 32 participants in total. It began in 2025-09-05 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the safety of ultra-low contrast coronary angiography in patients with pre-existing acute kidney injury.
Eligibility Criteria
Inclusion Criteria: * Hospitalized patients who have AKI at admission or who develop AKI during admission and require invasive coronary angiography will be included in the trial. Exclusion Criteria: * Stabilized renal function manifested by unchanged or downtrending serum creatinine during a 24-hour period prior to enrollment. * Contraindication for invasive coronary angiography other than AKI. * Percutaneous coronary intervention is indicated and cannot be postponed by 7 days. * Need for renal replacement therapy before coronary angiography or planned renal replacement therapy after coronary angiography (if premeditated before coronary angiography). * Administration of intravascular contrast media during 7 days prior to the coronary angiography or within 6 days after coronary angiography. * Pregnant patients, prisoners, cognitively impaired subjects, age below 18 years, unable or unwilling to provide informed consent.
Contact & Investigator
Zach Rozenbaum, MD
PRINCIPAL INVESTIGATOR
Tulane University
Frequently Asked Questions
Who can join the NCT05906758 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05906758 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 32 participants.
Is NCT05906758 currently recruiting?
Yes, NCT05906758 is actively recruiting participants. Contact the research team at zrozenbaum@tulane.edu for enrollment information.
Where is the NCT05906758 trial being conducted?
This trial is being conducted at New Orleans, United States, New Orleans, United States.
Who is sponsoring the NCT05906758 clinical trial?
NCT05906758 is sponsored by Tulane University. The principal investigator is Zach Rozenbaum, MD at Tulane University. The trial plans to enroll 32 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.